SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as investors react to a strong earnings report and the companys decision to maintain capital expenditure levels, which has effectively eased market anxiety regarding AI infrastructure spending. The community is actively debating the company's ability to drive long-term cloud and AI growth while highlighting its status as a stabilizing force amid broader market volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's broad regulatory approval of Anktiva, which marks a significant milestone in the company's global expansion and validates its therapeutic potential. While the community is actively debating the significance of international market entry versus the need for more substantial domestic clinical updates, many investors remain focused on upcoming quarterly earnings as a key indicator of commercial growth and a potential catalyst for price action.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to a profit miss and concerns over ballooning capital expenditures dedicated to AI infrastructure. While the company continues to see strong ad revenue growth, the market is actively debating whether these heavy infrastructure investments will yield long-term returns or continue to compress margins and free cash flow.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor interest driven by a series of record-breaking ABS issuances and strong analyst support that suggests the company is significantly undervalued relative to its fintech peers. The community remains focused on whether management's bullish execution and insider share purchases by the CEO will be enough to overcome broader macro volatility and lingering concerns about credit performance.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The market is experiencing extreme volatility driven by Fed policy uncertainty, regional conflicts, and mixed mega-cap earnings that have triggered aggressive algorithmic trading. Community sentiment is deeply divided, with many traders struggling to navigate the rapid sector rotations while debating the impact of upcoming economic data and institutional liquidity shifts.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing intense investor scrutiny ahead of earnings as concerns over ballooning AI infrastructure spending weigh on the stock. Market sentiment remains volatile as shareholders weigh the company's long-term cloud potential against short-term risks of elevated capital expenditures and regulatory pressure.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Market participants are reacting to heightened volatility fueled by the Federal Reserve's decision to hold rates steady, rising bond yields, and escalating Middle East tensions. The community remains deeply divided, with many debating whether the ongoing tech sector correction is a healthy rotation or a structural breakdown linked to AI capital expenditure concerns and global margin liquidation.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is facing significant volatility as investors digest mixed outcomes from an FDA advisory panel regarding the compounding of peptides. While the community is actively debating the long-term growth potential of these treatments, the stock is currently under pressure from heavy short-selling activity and concerns over the timing of regulatory approvals.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group Inc. is experiencing high volatility as shareholders react to the FDA accepting a resubmission for its melanoma treatment, with many community members debating whether this third attempt will yield a favorable outcome or another Complete Response Letter. Investors are closely monitoring upcoming advisory committee meetings and the potential for significant dilution, while the community remains polarized between those anticipating an approval-driven squeeze and others warning of a permanent decline.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Russell 2000 is currently grappling with heightened volatility as market participants weigh aggressive institutional put buying against resilience in small-cap sectors. Traders are heavily focused on the interplay between climbing bond yields, geopolitical instability, and anticipation of the upcoming Fed rate decision, which is forcing a shift in sentiment regarding whether small caps can maintain their current support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CAPR i know our heros are tired so I will say something after watching this whole thing. Many of the people voting had no connection and understanding of DMD. They tried to connect their personal understanding from heart attacks or different cardiac fields to understand DMD cardiomyopathy. Its soo different, they were way out of their depths so they just took the FDA at its very biased interpretation of the data. Since Capr made changes in each SAP that they submitted in accordance with the FDA directives, they get penalized and were forced to be interpreted by the earliest draft SAP before any enrollment started. Breaks my heart to see this level of idiocy making such a big decision that will destroy so many lives

Green_Dream

Patate Chaude

UnionFitter91

youknowwho

major

John Albrecht

Veg Green

KeralaPuthran

상후니

Robert

Michael

Baxter Crewz

Jeremy Jacob

avechristusrex_99

AGI2018

Crouching Tiger

tttggg

Mister E

Kishore Mosaliganti

Stephen Joshua

Magirus

Chessdoc

Mark Libka

StockTwits for iOS

Capricor Therapeutics Inc

 i know our heros are tired so I will say something after watching this whole thing. Many of the people voting had no connection and understanding of DMD. They tried to connect their personal understanding from heart attacks or different cardiac fields to understand DMD cardiomyopathy. Its soo different, they were way out of their depths so they just took the FDA at its very biased interpretation of the data. Since Capr made changes in each SAP that they submitted in accordance with the FDA directives, they get penalized and were forced to be interpreted by the earliest draft SAP before any enrollment started. Breaks my heart to see this level of idiocy making such a big decision that will destroy so many lives

StockTwits Web

@Bentradez -  A lot of lawsuits and crimnal referral. NS pharma would need money back and investors need money back.

 -  A lot of lawsuits and crimnal referral. NS pharma would need money back and investors need money back.